Registration study of JCAR017 in patients with B cell malignancies
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2017
At a glance
- Drugs JCAR 017 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 05 Jun 2017 According to A Juno Therapeutics media release, patients of core analysis group from a phase1 trial CTP700256222 will take part in this trial.
- 05 Jun 2017 According to Juno Therapeutics media release, this trial is expected to begin in the second half of 2017.
- 27 Apr 2017 According to a Celgene Corporation media release, Celgene and Juno Therapeutics plan to initiate this trial by year-end.